Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. - Wikidata - awgldk - TriplyDB

Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.

Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.

http://www.wikidata.org/entity/Q33896138

about

Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders Aldehyde Dehydrogenase 1 making molecular inroads into the differential vulnerability of nigrostriatal dopaminergic neuron subtypes in Parkinson's disease Aldehyde dehydrogenase inhibition generates a reactive dopamine metabolite autotoxic to dopamine neurons Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease.Fungal-derived semiochemical 1-octen-3-ol disrupts dopamine packaging and causes neurodegeneration Dysautonomia in Parkinson disease A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson's disease.Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy.VMAT2 and Parkinson's disease: harnessing the dopamine vesicle.Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).Aldehyde dehydrogenase 1a1 mediates a GABA synthesis pathway in midbrain dopaminergic neurons.Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function.Plasma biomarkers of decreased vesicular storage distinguish Parkinson disease with orthostatic hypotension from the parkinsonian form of multiple system atrophy.Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease.Chemopreventative effects of tetrahydrocurcumin on human diseases.Protective and toxic roles of dopamine in Parkinson's disease.Aldehyde dehydrogenase (ALDH) in Alzheimer's and Parkinson's disease.Catecholamine-Based Treatment in AD Patients: Expectations and Delusions.Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects.Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.Proteasome-mediated degradation of tyrosine hydroxylase triggered by its phosphorylation: a new question as to the intracellular location at which the degradation occurs.Linking Stress, Catecholamine Autotoxicity, and Allostatic Load with Neurodegenerative Diseases: A Focused Review in Memory of Richard Kvetnansky.Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.Cardiac sympathetic denervation without Lewy bodies in a case of multiple system atrophy.Antioxidant-Mediated Modulation of Protein Reactivity for 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopamine Metabolite.Oxidative stress and cellular pathologies in Parkinson's disease.Deuterium-reinforced polyunsaturated fatty acids improve cognition in a mouse model of sporadic Alzheimer's disease.Individual Amino Acid Supplementation Can Improve Energy Metabolism and Decrease ROS Production in Neuronal Cells Overexpressing Alpha-Synuclein.PCB95 and PCB153 change dopamine levels and turn-over in PC12 cells.3,4-Dihydroxyphenylacetaldehyde-Induced Protein Modifications and Their Mitigation by N-Acetylcysteine.

P2860

Q26826093-FD6BA142-F245-44CE-9D62-E887854127C4 Q26850502-75159E3C-4ECE-40A5-B655-08298E7E6D70 Q26852122-99BF51A1-AAAD-4C91-B991-E21936C1E517 Q28391762-5F77356C-C4EC-4EDC-BF0B-7E468A90D51C Q30581658-4F2E3969-5715-4295-8BBC-BFA00F3D92F2 Q33724885-1F6F4734-3C2F-4A0B-BAD4-975403FF4238 Q33919548-710481A8-3A8F-4783-A45A-BE34758A6C34 Q34065897-6B517693-4364-4239-8614-C228ADA9BB65 Q34384338-C6BD7A11-096E-4EB3-9D8D-45559D301E6C Q34463831-71B99AB6-AC16-4761-AF7C-B6CBEA50AEEA Q34560077-C1B8E15C-8828-4212-9EC3-779CC5A4DDC6 Q35181537-EE79C400-6C91-48B6-840D-CA148F5A6930 Q35557892-99B5C497-4FEC-4605-932F-126823977004 Q35638948-E82B856B-3CEE-4EFE-9BB9-1AAA0A47E112 Q35775723-88875E51-412A-46F0-8932-CAC152995BFB Q35810975-1406891E-1F1D-435E-BA80-365F0A473388 Q35999331-391658CF-49DE-4E71-BCC2-43F72117E33C Q36011221-4B8F1716-D045-4ABE-89DC-BC77A2EAB317 Q36282886-53FE25F2-1D7D-421A-BA2D-BE1AB38AA823 Q36497657-F2801C71-2D71-4A7E-AC99-B67F7F750F23 Q36559682-A17BE990-7243-45FB-BE82-5172F93C32AC Q37584540-E786CDE3-980D-43C9-9AF9-092DCE3B817B Q37595850-189F41B1-8E88-4F32-BE5D-A74BB93F2DD6 Q37711589-5D442FE6-53BB-423B-818B-906EF0934133 Q38162076-9B232458-97AD-4B8C-BCDB-A2893B831F5B Q38189127-EE03BEB6-8317-420A-88F5-324422B47380 Q38258298-8B21C82A-8CCF-4D04-AA1B-B3BB059F1C33 Q38497202-D78A1DAF-69FD-4CE6-B5F6-15C6B4AA47B3 Q38834545-B0651786-8420-497C-8432-679A6E593324 Q38926644-B0F6D5A3-4A9B-470A-AB9C-577AC032F9A6 Q39014535-BA79E0C2-891A-403A-A1EB-AA8B0F212DEF Q39294770-67A2FA37-1128-4A42-856F-26F73C5F084D Q41655727-FFB4B7E2-738D-40F5-B931-2754E9E272B4 Q42060109-5F26F6FF-757F-4519-BBAD-CA760DB37F5A Q42196555-285797DE-C459-4367-8653-9F52F285DFD8 Q46252606-A72E12BA-6B6B-4744-8167-2DD784828AFB Q46287807-75203EA2-C042-4B3E-AD52-A4ED03D70DCA Q46349223-FD71D323-116A-42B6-B54A-F0A5ABC96539 Q49887516-1D052FA9-CFD3-48C0-B423-9F748007AAAB Q55361950-D56E7D7E-C493-4BFA-A15D-2E1C39EDCCB8

P2860

Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.

http://www.wikidata.org/entity/Q33896138

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.

@ast

Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.

@en

type

label

Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.

@ast

Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.

@en

prefLabel

Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.

@ast

Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.

@en

P1433

Q33896138-0C7F76DD-3581-4C16-8E7C-D225CBCA321C

P1476

Q33896138-FF82D243-B9DC-4DEB-A1C5-E983ADDEAE3B

P2093

Q33896138-21DA80D2-F59A-4E35-A3DA-428C5607E26B

Q33896138-85CB3161-C2F5-46DA-84E0-D31D58158E51

Q33896138-9165C068-BD44-49E8-987B-F0EC45A29B62

Q33896138-94A35EA5-4AC6-48B4-9C44-19BAA4F274E0

Q33896138-A9F02CE7-5E26-4BF7-A629-7068FA936044

Q33896138-C35D4B26-240B-45FB-A0E8-D60DD92E4076

Q33896138-DA3F0C93-3D7A-49F5-931D-8382670C0F6A

Q33896138-DDB8AE27-9373-4BA7-B5B9-C9AA6E69DA6D

P2860

Q33896138-0102F60E-4132-42D8-BEAC-DA8F6FD1795C

Q33896138-07A9181E-48A2-429B-AB08-C1BD675EFF17

Q33896138-115B0F72-FF3C-438B-BBF2-7A36D7A53B10

Q33896138-1D840C3A-A5F9-46C1-BE8B-E2CA7E773ECE

Q33896138-24D8891F-3D24-4F4F-9782-4242BE99F59D

Q33896138-2C555D86-66B6-496E-B6FE-B525BAAF7BDE

Q33896138-2DA0B8CF-1395-4191-82A5-0CC4909663BA

Q33896138-307542C2-5C38-4B8A-BDE8-F8FB18E5B751

Q33896138-3415052E-F97B-4E8E-A11D-CE69E428F323

Q33896138-3CD244E9-4A04-4453-828F-E88AFC2608D5

P304

Q33896138-B22D458A-AED5-486A-A1D7-82A4608BE2E1

P31

Q33896138-430E8736-0918-481E-AFE0-A234840C41CD

P356

Q33896138-AF81F50D-1171-44F7-9054-EFAE219EE41C

P407

Q33896138-8BB84C3C-3989-43C8-8744-DFE7DB05642C

P433

Q33896138-67483AF8-8C21-4710-BDC8-BC0AF606BF6B

P478

Q33896138-CDB1655E-2432-4B47-ACC0-EAA98E253ACD

P50

Q33896138-70EBF056-74C4-422B-880B-D622F512D825

P577

Q33896138-5AEF26E1-F598-4DB1-A03B-A51C932FE915

P698

Q33896138-EDF6BBD2-EE3D-49C1-98E8-469B1D1B9CF5

P921

Q33896138-32D05DEE-F5F8-44F1-B32C-CD811262B4BA

Q33896138-847ba1f6-f2e9-4399-b9f1-a196d92efce3

P932

Q33896138-D5C2428F-D3BD-4B1D-9B72-AAA12B9A84E5

P356

P1433

Journal of Neurochemistry

P1476

Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.

@en

P2093

Courtney Holmes

http://www.w3.org/2001/XMLSchema#string

David S Goldstein

http://www.w3.org/2001/XMLSchema#string

Deborah C Mash

http://www.w3.org/2001/XMLSchema#string

Irwin J Kopin

http://www.w3.org/2001/XMLSchema#string

Patti Sullivan

http://www.w3.org/2001/XMLSchema#string

Randy Strong

http://www.w3.org/2001/XMLSchema#string

Shawn Alter

http://www.w3.org/2001/XMLSchema#string

Yehonatan Sharabi

http://www.w3.org/2001/XMLSchema#string

P2860

Proteome analysis of human substantia nigra in Parkinson's disease

Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine

Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease

Kinetics and crystal structure of catechol-o-methyltransferase complex with co-substrate and a novel inhibitor with potential therapeutic application

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

alpha-Synuclein locus triplication causes Parkinson's disease

Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration

In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133

Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata

Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease

P304

591-603

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JNC.12345

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

126

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23786406

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

4096629

http://www.w3.org/2001/XMLSchema#string